« Return to News | CROs/Service Providers

Top Stories for the Week of August 14th 2006

Tuesday, August 15, 2006 10:13 AM

Top News

SFBC Changes Name to PharmaNet Development Group

Now just emerging from a year of legal and financial blows and bad publicity, SFBC has decided to change its name to PharmaNet Development Group, pending shareholder approval later this month.

Quintiles Creates Strategic Biostatistics Unit

Raleigh, N.C.-based Quintiles has created a statistical working group called the Strategic Biostatistics Unit, which provides guidance to clients on using advanced statistical methods to adjust such variables as the number of patients, trial length, dosing arms and including safety and efficacy endpoints. Applying such methods to protocol design early can offer sponsors significant cost and time savings without statistically invalidating trial data. In addition, the unit’s expertise can develop adaptive clinical trial designs.

Other breaking news...

i3 Research adds another specialty…

eResearch Technology reported second quarter earnings

Company Profile: An interview with Remko van Leeuwen, director, business development, and Kees Groen, executive director of drug development IATEC.

To read the full articles for this issue or for more information on these and other breaking stories, please click here!

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.